Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Meetings

ACS hosts virtual gathering for pharma leaders

by Cal Trepagnier, ACS staff
April 16, 2021 | A version of this story appeared in Volume 99, Issue 14

 

On Feb. 23, the American Chemical Society held a virtual ACS Pharma Leaders meeting. Thirty-four biopharma industry leaders, representing 17 firms, participated in the meeting. This event is a complement to the annual face-to-face ACS Pharma Leaders meeting that has been held since 2003.

The general topic was “What Are We Learning from COVID-19?” Wendy Young, senior vice president of small-molecule drug discovery at Genentech, served as the moderator, and ACS CEO Thomas Connelly delivered welcoming remarks. Speakers included Sylvie Sakata, head of external research solutions at Pfizer; Oliver Thiel, executive director of process development drug substance technologies and pivotal and commercial synthetics at Amgen; William Morris, senior research scientist at Merck & Co.; and Richard Mackman, vice president of medicinal chemistry at Gilead Sciences.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.